Loading cancer entity…
Loading cancer entity…
Clinical trials
10,627 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,641)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05083208 | PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma | terminated | Phase 1 | 12 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 2, 2025 | clinicaltrials |
| NCT06304636 | Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma(DC15-MM-01) | terminated | Phase 1 | 4 | Cartesian TherapeuticsINDUSTRY | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05065047 | Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma | terminated | Phase 1 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT00776373 | Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies(UPCC 25406) | terminated | Phase 1 / Phase 2 | 4 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Nov 5, 2025 | clinicaltrials |
| NCT03837509 | INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 15 | Incyte CorporationINDUSTRY | 3 | Nov 4, 2025 | clinicaltrials |
| NCT04035434 | A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON) | terminated | Phase 1 / Phase 2 | 93 | CRISPR Therapeutics AGINDUSTRY | 6 | Oct 24, 2025 | clinicaltrials |
| NCT04582539 | To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma(LIMBER) | terminated | Phase 1 / Phase 2 | 22 | Incyte CorporationINDUSTRY | 3 | Oct 22, 2025 | clinicaltrials |
| NCT05169489 | A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL) | terminated | Phase 1 | 15 | Regeneron PharmaceuticalsINDUSTRY | 1 | Oct 21, 2025 | clinicaltrials |
| NCT04541017 | Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment | terminated | Phase 1 / Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Oct 16, 2025 | clinicaltrials |
| NCT04240704 | Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL | terminated | Phase 1 | 25 | Novartis PharmaceuticalsINDUSTRY | 7 | Oct 10, 2025 | clinicaltrials |
| NCT04702425 | VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma) | terminated | Phase 1 | 37 | Novartis PharmaceuticalsINDUSTRY | 9 | Oct 10, 2025 | clinicaltrials |
| NCT04405167 | Tasquinimod for the Treatment of Relapsed or Refractory Myeloma | terminated | Phase 1 | 30 | University of PennsylvaniaOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT06018129 | A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma | terminated | Phase 1 / Phase 2 | 9 | GenmabINDUSTRY | 2 | Sep 25, 2025 | clinicaltrials |
| NCT03769181 | A Study of Isatuximab-based Therapy in Participants With Lymphoma | terminated | Phase 1 / Phase 2 | 58 | SanofiINDUSTRY | 7 | Sep 23, 2025 | clinicaltrials |
| NCT05626322 | Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma | terminated | Phase 1 / Phase 2 | 6 | PfizerINDUSTRY | 3 | Sep 5, 2025 | clinicaltrials |
| NCT01198067 | Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia | terminated | Phase 1 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT05490043 | A Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas | terminated | Phase 1 | 33 | Antengene (Hangzhou) Biologics Co., Ltd.INDUSTRY | 1 | Aug 29, 2025 | clinicaltrials |
| NCT03015792 | Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant | terminated | Phase 1 | 18 | Mayo ClinicOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT02900651 | Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies | terminated | Phase 1 | 139 | Novartis PharmaceuticalsINDUSTRY | 10 | Aug 11, 2025 | clinicaltrials |
| NCT05032183 | Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | terminated | Phase 1 / Phase 2 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT06343376 | Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies | terminated | Phase 1 | 1 | Roswell Park Cancer InstituteOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT06588660 | ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 | 1 | University of WashingtonOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT04239092 | 9-ING-41 in Pediatric Patients With Refractory Malignancies. | terminated | Phase 1 | 40 | Actuate Therapeutics Inc.INDUSTRY | 1 | Jul 17, 2025 | clinicaltrials |
| NCT03287817 | Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma(ALEXANDER) | terminated | Phase 1 / Phase 2 | 52 | Autolus LimitedINDUSTRY | 2 | Jul 14, 2025 | clinicaltrials |
| NCT05153330 | Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL | terminated | Phase 1 | 55 | Biomea Fusion Inc.INDUSTRY | 5 | Jul 3, 2025 | clinicaltrials |
| NCT03786926 | Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas | terminated | Phase 1 | 53 | HutchmedINDUSTRY | 6 | Jun 26, 2025 | clinicaltrials |
| NCT05442580 | CART-38 in Adult AML and MM Patients | terminated | Phase 1 | 11 | University of PennsylvaniaOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT04735471 | A Phase 1 Study of ADI-001 in B Cell Malignancies(GLEAN-1) | terminated | Phase 1 | 34 | Adicet TherapeuticsINDUSTRY | 1 | Jun 18, 2025 | clinicaltrials |
| NCT03013491 | PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas | terminated | Phase 1 / Phase 2 | 196 | CytomX TherapeuticsINDUSTRY | 6 | Jun 17, 2025 | clinicaltrials |
| NCT05027594 | Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 | 5 | Nerviano Medical SciencesINDUSTRY | 1 | Jun 13, 2025 | clinicaltrials |
| NCT04986865 | A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas(PROBE) | terminated | Phase 1 | 31 | Antengene Biologics LimitedINDUSTRY | 2 | Jun 9, 2025 | clinicaltrials |
| NCT05265975 | A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL(SWATCH) | terminated | Phase 1 / Phase 2 | 54 | Antengene CorporationINDUSTRY | 1 | Jun 9, 2025 | clinicaltrials |
| NCT01350258 | Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps | terminated | Phase 1 / Phase 2 | 8 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT02953509 | Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | terminated | Phase 1 / Phase 2 | 178 | Gilead SciencesINDUSTRY | 3 | May 29, 2025 | clinicaltrials |
| NCT04892264 | Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma | terminated | Phase 1 | 5 | Mayo ClinicOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT03994705 | Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 | 20 | Cartesian TherapeuticsINDUSTRY | 1 | May 15, 2025 | clinicaltrials |
| NCT01352312 | Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma | terminated | Phase 1 | 10 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT04464798 | A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas | terminated | Phase 1 | 62 | CelgeneINDUSTRY | 6 | Apr 29, 2025 | clinicaltrials |
| NCT02875223 | A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas | terminated | Phase 1 | 75 | CelgeneINDUSTRY | 5 | Apr 20, 2025 | clinicaltrials |
| NCT03486067 | Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma | terminated | Phase 1 | 183 | CelgeneINDUSTRY | 6 | Apr 17, 2025 | clinicaltrials |
| NCT03492125 | A Study Of The Selective PKC-β Inhibitor MS- 553 | terminated | Phase 1 / Phase 2 | 60 | MingSight Pharmaceuticals, IncINDUSTRY | 1 | Apr 10, 2025 | clinicaltrials |
| NCT04896658 | Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 10 | University of Maryland, BaltimoreOTHER | 1 | Apr 3, 2025 | clinicaltrials |
| NCT04553692 | Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers | terminated | Phase 1 | 272 | IGM Biosciences, Inc.INDUSTRY | 5 | Mar 28, 2025 | clinicaltrials |
| NCT05296525 | Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL | terminated | Phase 1 / Phase 2 | 13 | Gamida Cell ltdINDUSTRY | 1 | Mar 25, 2025 | clinicaltrials |
| NCT04975399 | Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma | terminated | Phase 1 | 26 | CelgeneINDUSTRY | 3 | Mar 24, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Dec 2, 2025source: clinicaltrials